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Obesity is associated with infiltration of macro-
phages into adipose tissue (AT), contributing to insu-
lin resistance and diabetes. However, relatively little
is known regarding the origin of AT macrophages
(ATMs). We discovered that murine models of
obesity have prominent monocytosis and neutro-
philia, associated with proliferation and expansion
of bone marrow (BM) myeloid progenitors. AT trans-
plantation conferred myeloid progenitor proliferation
in lean recipients, while weight loss in both mice and
humans (via gastric bypass) was associated with a
reversal of monocytosis and neutrophilia. Adipose
S100A8/A9 induced ATM TLR4/MyD88 and NLRP3
inflammasome-dependent IL-1b production. IL-1b
interacted with the IL-1 receptor on BMmyeloid pro-
genitors to stimulate the production of monocytes
and neutrophils. These studies uncover a positive
feedback loop between ATMs and BM myeloid pro-
genitors and suggest that inhibition of TLR4 ligands
or the NLRP3-IL-1b signaling axis could reduce AT
inflammation and insulin resistance in obesity.
INTRODUCTION
Obesity is one of the most prevalent diseases globally, leading
to metabolic syndrome (MetS), type 2 diabetes (T2D), and
increased risk of cardiovascular disease (CVD) (Haffner et al.,
1990). Obesity-associated inflammation is widely regarded asCone of the major factors driving insulin resistance (IR) and the
onset of T2D (Osborn and Olefsky, 2012). A hallmark of inflam-
mation in obesity is the accumulation of visceral adipose tissue
(VAT) macrophages (ATMs) (Weisberg et al., 2003). As VAT path-
ologically expands in obese subjects, ATMs appear to undergo a
phenotypic switch from resident ATMs to what is generally
referred to as an inflammatory phenotype (Lumeng et al.,
2007). This expansion of inflammatory ATMs, along with the
decrease in anti-inflammatory T-regulatory cells in the VAT, re-
sults in an imbalanced environment and is thought to drive IR
and the progression to T2D in obese subjects (Osborn and Olef-
sky, 2012).
Overexpression of the key monocyte/macrophage chemoat-
tractant MCP-1 in the VAT results in macrophage accumulation,
increased VAT inflammation, and impaired insulin sensitivity
(Kamei et al., 2006). In contrast, inhibiting macrophage recruit-
ment using Ccr2/ mice (receptor for MCP-1) protects mice
from IR (Weisberg et al., 2003). This implies that macrophage
recruitment pathways are important in inflammation-driven IR.
More evidence to support the role of macrophage inflammation
in IR has arisen from studies depleting ATMs (Weisberg et al.,
2003) or inflammatory CD11c+ ATMs (Patsouris et al., 2008) or
restricting their inflammatory capabilities (Arkan et al., 2005; Sol-
inas et al., 2007; Vandanmagsar et al., 2011; Wen et al., 2011).
Reduced ATM-driven inflammation protects from diet-induced
IR. However, little is known about the source of ATMs and the
signaling processes that lead to their accumulation in VAT.
There is a strong association between obesity, diabetes, and
leukocytosis, particularly of the myeloid lineage (Ford, 2002;
Kullo et al., 2002; Ohshita et al., 2004; Schmidt et al., 1999).
We recently reported that enhanced myelopoiesis in type 1 dia-
betes (T1D) mouse models significantly impairs the resolution of
atherosclerosis (Nagareddy et al., 2013). Increased numbers ofell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc. 821
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development of T2D (Schmidt et al., 1999). Obese children
also present with increased levels of circulating monocytes
(Schipper et al., 2012). Together, these pieces of evidence sug-
gest that there may be a causal relationship between leukocy-
tosis, particularly monocytosis, and the accumulation of ATMs
and IR. We previously have shown that expansion and prolifera-
tion of bone marrow (BM) hematopoietic stem and progenitors
results in monocytosis and is associated with enhanced athero-
genesis (Murphy et al., 2011; Yvan-Charvet et al., 2010). How-
ever, the role of myeloid progenitor cell proliferation and
monocytosis in driving ATM accumulation in obesity has not
been examined.
We hypothesized that VAT inflammation results in the release
of inflammatory mediators that communicate directly with he-
matopoietic progenitor cells in the BM to promote leukocytosis.
We reasoned that this would set up a feed-forward loop to pro-
vide the adipose tissue with more monocytes/macrophages
that, in turn, trigger adipose inflammation and promote IR.
RESULTS
Monocytosis in Obesity Is Associated with Enhanced
Myelopoiesis
To determine if obesity is associated with leukocytosis, we
studied the leptin-deficient Ob/Ob mouse. Ob/Ob mice had an
approximately 2.5-fold increase in the numbers of circulating
monocytes (both Ly6-Chi and Ly6-Clo) and neutrophils com-
pared to their lean controls (Figures 1A and 1B). The increased
numbers of circulating myeloid cells were due to enhanced pro-
duction by hematopoietic progenitor cells. Ob/Ob mice had a
global expansion of hematopoietic stem and multipotential pro-
genitor cells (HSPCs), common myeloid progenitors (CMPs),
and granulocyte macrophage progenitors (GMPs) compared to
the lean controls (Figures 1C and 1D; flow cytometry identifica-
tion of cell populations are shown in Figures S1A and S1B
available online). This was accompanied by increased prolifera-
tion of CMPs and GMPs, but not HSPCs (Figure 1E). The
expansion of dormant HSPCs is consistent with increased reten-
tion in the BM (Ferraro et al., 2011). A similar monocytosis,
expansion and proliferation of myeloid progenitors, was found
in the leptin-receptor-deficient db/db mouse model (Figures
S1C–S1E).
Increased Myelopoiesis Is Not due to Leptin Deficiency
or Hyperglycemia
Wenext examined if leptin deficiency causedmonocytosis by re-
plenishing leptin in Ob/Ob mice (intraperitoneally [i.p.] 1 mg/kg/
day for 7 days). Leptin did not did not reduce blood monocytes
(Table S1) or affect plasma cholesterol, but it did lower triglycer-
ides, blood glucose, and food intake and led to a slight reduction
in body weight (the mice were still obese versus lean controls)
(Table S1; data not shown). To further assess whether leptin defi-
ciency in myeloid cells is the cause of monocytosis, we con-
ducted BM transplant (BMT) studies using BM from wild-type
(WT) and Ob/Ob mice (Figure 2A). Transplantation of WT or
Ob/Ob BM into WT recipients did not promote monocytosis,
while transplantation of WT or Ob/Ob BM into Ob/Ob recipients
increased levels of circulating monocytes (Figure 2B). These822 Cell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc.results were also mirrored in the abundance and proliferation
of hematopoietic stem and progenitor cells (Figures 2C and
2D). These data confirm that defective leptin signaling does not
cause monocytosis in obesity.
We have previously shown in mouse models of T1D that hy-
perglycemia promotes leukocytosis (Nagareddy et al., 2013).
To examine if hyperglycemia caused monocytosis in obesity,
we treated Ob/Ob mice with a sodium glucose cotransporter 2
inhibitor (SGLT2i; dapagliflozin 25 mg/kg, for 4 weeks) to reduce
blood glucose. The SGLT2i normalized blood glucose levels
(Figure 2E) but failed to lower the number of circulating leuko-
cytes (Figure 2F). These findings are different from those we re-
ported in the STZ T1D model, where glucose lowering did
reverse leukocytosis, most likely because glucose levels were
much higher (500 mg/dl) than in the present study (250 mg/dl)
(Nagareddy et al., 2013).
Adipose Tissue from Ob/Ob Mice Drives Leukocytosis
To test whether monocytosis was due to signals emanating from
VAT, we first cultured VAT from lean or Ob/Obmice and used the
conditionedmedia for in vitro BMprogenitor proliferation assays.
Incubation of BM cells with conditioned media from Ob/Ob
mouse VAT significantly increased GMP proliferation compared
to media from lean mouse VAT (Figure 2G). To confirm this
in vivo, we conducted fat pad transplant (FPT) studies using
equal amounts of VAT from WT or Ob/Ob mice as described
elsewhere (Gavrilova et al., 2000; Klebanov et al., 2005) (Fig-
ure 2H). After approximately 10 days, the initial inflammation
due to the surgery had subsided, and circulating monocyte
levels of mice that received fat from WT mice had returned to
normal (Figure 2I). In contrast, WT mice that received an equal
amount of VAT from Ob/Ob mice developed monocytosis (Fig-
ure 2I), which was associated with increased numbers and pro-
liferation of myeloid progenitor cells (Figures 2J and 2K). We also
performed FPT experiments using subcutaneous adipose tissue
(SAT) and found that obese SAT induced leukocyte production,
but to a lesser extent compared to what we observed using
VAT (Figures S2A–S2C), consistent with previous studies sug-
gesting that SAT is less inflammatory than VAT (Osborn andOlef-
sky, 2012). While we acknowledge that the FPT studies should
be interpreted with caution, as macrophages are also involved
in tissue remodeling and angiogenesis, collectively, these data
suggest that factors originating from the VAT signal to the BM
to promote monocyte production.
Leukocytosis in Diet-Induced Obesity
To confirm thatmonocytosis was due to obesity, we fedWTmice
a high-fat diet (HFD; 60% kcal) for 20 weeks (diet-induced
obesity; DIO) in parallel with lean controls fed a low-fat diet
(LFD; 10% kcal). DIO mice weighed an average of 55 g, signifi-
cantly greater than their lean counterparts that averaged 34 g.
Similar to Ob/Ob mice, obesity in DIO mice was associated
with >2.5-fold increase in the numbers of circulating monocytes
and neutrophils (Figures 3A and 3B). This was accompanied by
an increase in the numbers and proliferation of CMPs and
GMPs but not HSPCs (Figures 3C–3E). We also performed an
FPT study using VAT from DIO and lean mice (Figure 3F) and
observed monocytosis and neutrophilia along with expansion
of CMPs and GMPs in the BM in the DIO FPT recipients (Figures
Figure 1. Leukocytosis in Obese Mice Is due to Enhanced Myelopoiesis: Ob/Ob or Lean Controls on a Chow Diet
(A and B) In (A), representative flow cytometry plots indicating monocyte and neutrophil populations are shown, and in (B), they are quantified in the accom-
panying graph. N, neutrophil; M, monocyte; Lo, Ly6-Clo; Hi, Ly6-Chi.
(C and D) In (C), representative flow cytometry plots depicting the BM progenitor cells are shown, and in (D), they are quantified. MPC, myeloid progenitor cell.
(E) Cell cycle analysis of the hematopoietic cells using DAPI. All data are means ± SEM; n = 5 per group. *p < 0.05. See also Figure S1.
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cytosis is obesity dependent.
Weight Loss Decreases Leukocytes in Obese Mice and
Humans
VAT inflammation is reduced after weight loss (Berg and
Scherer, 2005); thus, we examined the effect of weight loss on
leukocyte levels in DIO mice. After 16 weeks of an HFD, mice
were returned to a LFD. This led to a weight loss of 5 g over
3 weeks and a significant reduction in VAT, comparable to levels
observed in lean controls (Figures 3I and 3J). Associated withCweight reduction was a significant decrease of both monocyte
and neutrophil levels (Figures 3K and 3L). To demonstrate the
potential to translate our findings to humans, we examined
leukocyte levels in 13 obese subjects before and 18 months
after bariatric surgery (9 had Roux-en-Y gastric bypass, 2 had
adjustable gastric banding, and 2 had sleeve gastrectomy).
The subjects had an average weight loss of 26.7% of their
total body weight and a significant reduction in monocyte and
neutrophil counts (Table S2). The decrease in circulating
monocytes correlated with improvement in IR as calculated by
homeostasis model assessment-IR (Figure S2D). While theseell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc. 823
Figure 2. Adiposity Drives Leukocytosis
(A–D) In (A), an experimental overview is shown: (1)WT or (2) Ob/Ob BMwas transplanted intoWT recipients. (3)WT or (4) Ob/Ob BMwas transplanted into Ob/Ob
recipients. BM was allowed to reconstitute for 5 weeks. (B) Monocyte levels, (C) BM progenitors, and (D) cell cycle analysis of BM progenitors. All data are
means ± SEM; n = 5 per group. *p < 0.05.
(E and F) WT and Ob/Ob mice were treated with an SGLT2i. (E) Blood glucose levels. (F) Blood leukocytes. All data are means ± SEM; n = 5 per group. *p < 0.05.
(G) Conditioned media from cultured lean or Ob/Ob VAT was incubated (10% v/v) with BM progenitor cells, and GMP proliferation was measured by EdU
incorporation. n = 6 (independent conditioned media treatments from the VAT of six mice per group).
(H–K) In (H), an experimental overview is shown: FPT: Equal portions of VAT from lean or Ob/Ob mice were transplanted into lean WT recipients. (I) Monocyte
levels were monitored weekly for 4 weeks. After 4 weeks, the (J) abundance and (K) cell cycle of the BM progenitor cells were determined by flow cytometry. All
data are means ± SEM; n = 5 per group. *p < 0.05. See also Figure S2 and Table S1.
Cell Metabolism
Obesity Drives Myelopoiesis
824 Cell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc.
Figure 3. Adipose Tissue of HFD-Fed Mice Promotes Monocytosis
(A–E) WT mice were fed an LFD (Lean) or an HFD (DIO) for 20 weeks. (A) Representative flow cytometry plots depicting blood leukocyte populations and (B)
quantification. (C) Representative flow cytometry plots depicting BM progenitor cells and (D) the abundance quantified. (E) Cell cycle analysis on the BM pro-
genitor cells. All data are means ± SEM; n = 6 lean and 12 DIO mice per group. *p < 0.05.
(F–H) In (F), an experimental overview is shown. FPT: Equal portions of VAT were transplanted into lean WT recipients for 4 weeks. (G) Blood leukocyte levels and
(H) BM progenitors. All data are means ± SEM; n = 6 per group. *p < 0.05. Monos, monocytes; Neutros, neutrophils.
(I–L) Sixteen-week HFD-fed DIO obese mice were randomized into two groups: DIO-control (DIO-C), continued on an HFD; or DIO-weight loss (DIO-WL),
switched to a chow diet to promote weight loss for 3 weeks. (I) Changes in body weight and (J) VAT mass after 3 weeks of weight loss. Circulating (K) monocyte
and (L) neutrophil levels. Pre, pre-weight loss; Post, post-weight loss. All data are means ± SEM; n = 6 per group. *p < 0.05. See also Figure S2 and Table S2.
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with our hypothesis that obesity causes monocytosis and
neutrophilia.CAdipose Factors that Increase BM Proliferation
In order to determine the potential factors that are released from
VAT, we conducted an mRNA analysis of a number of genes.ell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc. 825
Figure 4. Inflammatory Gene Expression in
the VAT
(A–C) Lean or Ob/Obmice were fed a chow diet for
12 weeks. Gene expression from (A) total VAT, (B)
VAT SVCs, and (C) VAT adipocytes was quantified
by quantitative PCR (qPCR).
(D) Plasma levels of S100A8/A9 in lean and obese
mice.
(E)S100a8 and S100a9mRNA expression in blood
neutrophils isolated by fluorescence-activated cell
sorting. All data aremeans ± SEM; n = 6 per group.
*p < 0.05. See also Figure S3.
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berg et al., 2003), the VAT from obese mice displayed increased
expression of a number of inflammatory genes and macrophage
markers (Figure 4A; Figure S3A). However, the most striking in-
crease was in the expression of S100a8/a9 (Figures 4A and
S3A), the proteins that we recently demonstrated as major
players in hyperglycemia-induced monocytosis (Nagareddy
et al., 2013). To determine the source of S100a8/a9 within the
adipose tissue, we separated the macrophage-rich stromal
vascular cells (SVCs) from adipocytes and found that, while
S100a8 and S100a9 were equally increased in the SVCs, only
S100a8 was upregulated in the adipocytes (Figures 4B and
4C). As expected, Tnf-a, Mcp-1, and genes of the inflamma-
some/interleukin (IL)-1b pathway were also increased in obese
adipose SVCs (Figure 4B). It is surprising that S100A8/A9 levels
did not increase in the plasma (Figure 4D). In addition, the
expression of S100a8/a9 in circulating neutrophils, the main
source of S100A8/A9 in mice with T1D (Nagareddy et al.,
2013), was not increased in obese mice (Figure 4E). Together,
these findings suggest that, if S100A8/A9 are eliciting a biolog-
ical response, it is confined to the adipose tissue.
We also measured the plasma levels of S100A8/A9 in a series
of human subjects, which were stratified by their body mass
index (BMI) and found no difference between lean and obese
subjects (Figure S3B). However, as noted in obesemice, a signif-
icant increase in S100A8/A9 levels was observed in the VAT from
obese humans with insulin-resistant diabetes compared to
healthy lean subjects (mean ± SD for lean versus obese BMI:
22.6 ± 1.3 versus 25.7 ± 1.4; p < 0.05) (Figures S3C and S3D).
MyD88-Dependent Toll-like Receptor 4 Signaling Is
Required for Obesity-Driven Leukocytosis
Since S100a8/a9 can induce inflammatory cytokines by
engaging pattern recognition receptors (PRRs), including toll-
like receptor 4 (TLR4) (Vogl et al., 2007) and the receptor for
advanced glycation end products (RAGE) (Boyd et al., 2008),826 Cell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc.we examined the role of PRRs in
obesity-associated leukocytosis. In T1D,
S100A8/A9 binds to RAGE (but not
TLR4) on CMPs initiating myelopoiesis
(Nagareddy et al., 2013); however, we
did not observe increased RAGE expres-
sion on CMPs from either DIO or Ob/Ob
mice (data not shown), which is likely
due to these mice having only moderateincreases in blood glucose levels. We assessed the importance
of TLR4 and RAGE in BM- and hematopoietic-derived VAT cells
on leukocytosis in obese mice through a series of BMT and FPTs
(see Figure 5A for the experimental outline). All recipient mice re-
mained obese and had similar body weights between the
different BM genotypes (mean ± SEM for body weight at the
end of the study: WT, 55.5 ± 0.9; Rage/, 55.9 ± 3.3; Tlr4/,
55.6 ± 0.8). Ob/Ob mice transplanted with BM from mice car-
rying a mutant form of TLR4 (Tlr4/) (Poltorak et al., 1998) had
significantly less monocytes and neutrophils, while mice trans-
planted with WT or Rage/ BM had comparable levels (Fig-
ure 5B). The Tlr4/ BMT mice also had improved glucose
tolerance compared to the WT and Rage/ BMT mice (Fig-
ure 5C). We also found positive correlations between monocyte
levels, fasting blood glucose, and ATMs (Figures S4A–S4C), but
not with body weight as expected, since the recipients were Ob/
Ob mice (data not shown).
TLR4 has two main downstream signaling pathways, MyD88
and TRIF/TRAM (Takeuchi and Akira, 2010). To determine which
pathway downstream of TLR4 was important in driving leukocy-
tosis in obesity, we preformed BMTs from mice deficient in
Myd88 or Cd14 (essential for lipopolysaccharide (LPS)/TLR4 to
internalize and signal via TRIF/TRAM [Kagan et al., 2008; Zanoni
et al., 2011], also reported to be involved in microbe-induced IR
[Cani et al., 2007]). Ob/Ob mice that receivedMyd88/ BM had
significantly less circulating monocytes and neutrophils than WT
or Cd14/ BMT mice (Figure 5D). Again, lower levels of these
leukocytes were associated with improved glucose tolerance
in these mice compared to Ob/Ob mice that received BM from
either WT or Cd14/ BMT mice (Figure S4D). TLR4 and
MyD88 deficiency in hematopoietic cells also resulted in fewer
progenitor cells that were proliferating at a lower rate compared
to WT BM recipients (Figures 5E and 5F). We also found fewer
macrophages in the VAT of the Ob/Ob mice transplanted with
Tlr4/ or Myd88/ BM (Figure 5G). Next, we profiled the in-
flammatory genes of the SVCs of the VAT from Ob/Ob mice
Figure 5. MyD88-Dependent TLR4 Signaling Is Required for Leukocytosis in Obesity
(A) Experimental overview: Ob/Ob mice were transplanted with BM from donor mice (1–5) and allowed to reconstitute for 5 weeks before blood leukocytes were
assessed. VAT was harvested from Ob/Ob mice after BMT (1 and 2), and equal portions of VAT were transplanted into lean WT mice.
(B and C) Ob/Ob mice BMT with WT, Tlr4/, or Rage/ BM. (B) Blood leukocyte levels and (C) OGTT (1 g/kg of glucose).
(D) Blood leukocyte levels in Ob/Ob BMT with WT, Myd88/, or Cd14/ BM.
(E and F) In (E), an abundance of hematopoietic progenitor cells in the BM is shown. (F) Cell cycle analysis.
(G) Macrophage abundance in the VAT was assessed by immunohistochemistry using anti-Mac3 antibody; 203 objective.
(H) Expression of inflammatory genes in the SVCs of the VAT from Ob/Ob BMT mice [1 and 2 from (A)].
(I–K) FPT of VAT fromOb/Obmice [1 and 2 from (A)]. (I) Blood leukocyte levels, (J) BMprogenitor abundance, and (K) cell cycle analysis. All data aremeans ± SEM;
n = 6 per group. *p < 0.05. See also Figure S4.
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Obesity Drives Myelopoiesisthat received WT or Tlr4/. As expected, we observed a signif-
icant reduction in the expression of TNF-a, Mcp-1, Il-1b, and
Nlrp3, a key component of the inflammasome (Figure 5H). There
were no changes in the expression of S100a8/a9 in the SVCs
(data not shown), suggesting that the expression of these genes
is not regulated by TLR4 in the VAT.
To determine the role of hematopoietic TLR4 specifically in the
VAT in promoting monocytosis in obesity, we transplanted the
VAT from the Ob/Ob mice that received either WT or Tlr4/
BM into lean WT recipients (see overview Figure 5A, 1 and 2).
Mice that received the VAT containing Tlr4/ cells of hemato-
poietic origin were protected from developing monocytosis
and did not display expansion or increased proliferation of their
BM progenitor cells (Figures 5I and 5K). Furthermore, condi-
tioned media from the VAT of Ob/Ob transplanted with Tlr4/
BM failed to induce myelopoiesis in vitro compared to condi-
tioned media from Ob/Ob mice transplanted with WT BM as
measured by incorporation of EdU+ into their GMPs (Figure S4E).
CD11c+ ATMs Promote Myelopoiesis in Obesity
TLR4 is expressed in a variety of hematopoietic cells, including
HSPCs, CMPs, GMPs (Nagai et al., 2006), and mature myeloid
cells (Takeuchi and Akira, 2010) including ATMs (Nguyen et al.,
2007). It is possible that signals arising from the VAT (e.g.,
S100A8/A9) could bind to TLR4 on any of these cells to promote
myelopoiesis. Thus, we used cell-specific knockouts ofMyd88 in
mature myeloid cells transplanted into Ob/Ob recipients to
assess a role of macrophages and dendritic cells (outlined in
Figure 6A), i.e., Myd88flox/flox (controls), Myd88flox/flox LysM Cre
BM (deletion in neutrophils, monocytes, and macrophages),
and Myd88flox/flox CD11c Cre BM (deletion in dendritic cells,
CD11c+ macrophages, and, to a lesser extent, monocytes and
neutrophils) (Hoshi et al., 2012; Figure 6B shows a schematic
overview of the two Cres and Myd88 expression levels from
hematopoietic cells as they mature). Ob/Ob mice that received
BM with Myd88 deletion via LysM Cre or CD11c Cre had fewer
circulating monocytes and neutrophils (Figure 6C). These mice
also had a reduced number and proliferation of GMPs in the
BM (Figures 6D and 6E). These data confirm that TLR4 signaling
in mature myeloid cells—especially the inflammatory CD11c+
macrophages (Hoshi et al., 2012) as described by Patsouris
et al. (2008), but not hematopoietic progenitor cells—is required
to promote monocytosis in obesity.
As TLR4 signaling in ATMs appeared to be required for
obesity-driven myelopoiesis, we reasoned that depletion of
ATMs should prevent VAT-induced monocytosis in FPT
experiments.
A strategy to deplete ATMs by administration of clodronate
(CLO) liposomes directly into the fat failed as injection of CLO
liposomes intraperitoneally to Ob/Ob mice (Feng et al., 2011)
also decreased circulating monocytes in both Ob/Ob and WT
mice (data not shown), suggesting that it had reached the circu-
lation. To circumvent this complication, we removed the VAT
from Ob/Ob mice pretreated with either PBS or CLO liposomes,
extensively washed the isolated VAT (to remove any residual
liposomes), and then transplanted equal amounts of VAT into
lean mice (Figure 6F). To confirm that the transplanted fat was
free of ATMs, we examined the abundance of dendritic cells
(DCs: CD45+CD11c+F4/80), ATMs (Mac: CD45+CD11cF4/828 Cell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc.80+), and CD11c+ ATMs (CD11c+ Mac: CD45+CD11c+F4/80+)
by flow cytometry and found a significant decrease in both
ATM populations (Figure 6G). We also found fewer F4/80+ cells
by immunohistochemistry and a decrease in the mRNA expres-
sion of F4/80 and Cd68, confirming ATM depletion (Figures 6H
and 6I). Mice that received CLO-treated VAT had fewer circu-
lating monocytes and neutrophils compared to those that
received VAT from PBS-treated donor mice (Figure 6J), which
was accompanied by a decrease in number and proliferation
of the BM progenitors cells (Figures 6K and 6L). To support
this finding, we also cultured BM progenitor cells in DIO adipo-
cyte (ATMdevoid)-conditionedmedia and examined GMP prolif-
eration. We observed significantly less GMP proliferation when
the GMPs were incubated in the adipocyte-only conditioned
media compared to GMPs incubated in conditioned media
from total VAT (Figure S5A). Together, these data suggest that
ATMs are essential to promote myelopoiesis in obesity.
The IL-1b/NLRP3 Inflammasome Pathway Drives
Leukocytosis in Obesity
Consistent with recent reports (Vandanmagsar et al., 2011; Wen
et al., 2011), we found that key genes involved in the IL-1b
pathway were increased in the SVCs of obese mice (i.e., Il-1b
and Nlrp3; Figure 4B). Moreover, the expression of these same
genes was markedly decreased in the SVCs of Tlr4/ trans-
planted Ob/Ob mice (Figure 5H). Therefore, we hypothesized
that the IL-1b pathway was playing a major role in promoting
leukocytosis in obesity. More evidence to suggest this comes
from the recent finding that the expression of the Nlrp3 inflam-
masome and Il-1b in VAT are dramatically reduced in mice and
humans undergoing weight loss (Vandanmagsar et al., 2011),
which, we report here, also coincides with decreased monocyte
and neutrophil levels (Figures 3K and 3L; Table S2).
To address the role of IL-1b in obesity-driven monocytosis, we
transplanted BM from WT or Nlrp3/ mice into Ob/Ob recipi-
ents. In line with our hypothesis, the Ob/Ob mice that received
Nlrp3/ BM had significantly fewer circulating leukocytes and
a reduction in the BMprogenitors than Ob/Obmice that received
WT BM (Figures 7A–7C).
Next, we assessed the IL-1b signaling pathway by placing WT
and IL-1 receptor (IL-1R) knockout mice on an HFD for 6months.
Both groups were obese (>60 g), with the IL-1r/mice weighing
slightly more. We observed significantly fewer monocytes and
neutrophils, along with BM progenitors, in DIO IL-1r/ mice
compared to the DIO WT mice (Figures 7D–7F).
IL-1b could be acting locally within the VAT to cause monocy-
tosis via a secondary signal such as a colony-stimulating factor,
or it could be traveling to and interacting with myeloid progenitor
cells in the BM. To explore the latter option, we profiled the cell
surface expression of the IL-1R on the CMPs and GMPs in the
BM of lean and DIO WT mice and found an increase on CMPs
and GMPs from DIO mice (Figure 7G). No interaction of the IL-
1R antibodywith the IL-1r/BMprogenitor cells was seen, con-
firming specificity (data not shown). While upregulation of the
IL-1R on CMPs/GMPs does not confirm that IL-1b is acting
directly on the BM progenitor cells to promote their proliferation,
we did find that IL-1b could induce the proliferation of GMPs
in vitro in an IL-1R-dependent manner (Figure S5B), and we
were able to detect increased circulating levels of IL-1b in DIO
Figure 6. TLR4/MyD88 Signaling in CD11c+ ATMs Drives Leukocytosis in Obesity
(A) Experimental outline: Ob/Obmice were transplanted with BM fromMyd88flx/flx,Myd88flx/flx LysMCre, orMyd88flx/flxCD11c Cre and allowed to reconstitute for
5 weeks.
(B) Schematic overview of the LysM- and CD11c Cre-induced deletion of Myd88 in the respective myeloid cells and the overlapping CD11c+ macrophage.
(C–E)Representedhereare (C) blood leukocyte levels, (D)BMprogenitor abundance, and (E) cell cycleanalysis.All dataaremeans±SEM;n=6pergroup. *p<0.05.
(F–L) In (F), an experimental overview is shown: Ob/Ob mice were injected i.p. with PBS or CLO liposomes (to deplete ATMs). The VAT was harvested, washed,
and transplanted into leanWTmice for 4 weeks. (G) Flow cytometry plots of the ATM subsets (parent gate CD45+), (H) F4/80 staining of the VAT, and (I) F4/80 and
Cd68 mRNA expression in the VAT. (J) Circulating blood monocyte levels, (K) BM progenitor abundance, and (L) proliferation after transplantation. All data are
means ± SEM; n = 5 per group. *p < 0.05. See also Figure S5A.
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Obesity Drives Myelopoiesismice (means ± SEM: WT, 4.5 ± 0.5 pg/ml; DIO, 7.95 ± 0.6 pg/ml;
n = 6, p < 0.05). Moreover, in an in vitro competitive GMP
proliferation experiment, we found that WT CD45.1 GMPs
outgrew IL-r/CD45.2 GMPs in response to IL-1b (Figure S5C).
To explore this further, we performed in vivo competitive
BMT studies (cBMT) in Ob/Ob recipients. We found that WT
CD45.1 GMPs outgrew IL-1r/ CD45.2 progenitors in the
BM (Figure 7H), producing2-fold more monocytes and neutro-
phils in the blood (Figure 7I), which resulted in more WT CD45.1
ATMs (Figure S5D). This confirms that IL-1b is acting in a cell-
extrinsic fashion to promote the proliferation of GMPs and
CMPs (which require the IL-1R) in obese mice to produce
myeloid cells.
Our data along with others (Vandanmagsar et al., 2011; Wen
et al., 2011) suggest that the production of IL-1b in obesity orig-
inates from the ATMs. As IL-1b is downstream of TLR4 signaling,
we questioned if S100A8/A9, known ligands of TLR4, could
induce Il-1b gene expression. We cultured BM-derived macro-
phages from WT, Tlr4/, and Myd88/ mice and stimulated
them with S100A8/A9. The expression of Il-1b, Nlrp3, and Il-1r,
along with other downstream TLR4 genes such as Tnf-a and
Mcp-1, was induced by S100A8/A9 (Figure 7J). Tlr4/ and
Myd88/ macrophages failed to respond to S100A8/A9 stimu-
lation (Figure 7J).
Finally, to determine if the IL-1b/IL-1R pathway could be ther-
apeutically targeted to reduce circulating leukocytes, we treated
DIO mice with the IL-1R antagonist (IL-1Ra, Anakinra). WT mice
were fed a HFD for 16 weeks before being treated with Anakinra
(i.p. 7.5 mg/kg daily for 10 days). Administration of Anakinra
significantly reduced monocyte and neutrophil levels along
with fewer BM progenitors compared to vehicle-treated mice
(Figures 7K, S5E, and S5F). The abundance of ATMS was also
significantly reduced in the Anakinra-treated mice (Figure S5G).
It is somewhat surprising that the short-term administration of
Anakinra also led to a significant improvement in glucose
handling as determined by an oral glucose tolerance test
(OGTT) (Figure 7L).
Together, these findings point to a role for S100A8/A9 and
possibly other TLR4 ligands present in obese VAT to induce
the expression of Il-1b and the Nlrp3 inflammasome in ATMs
via TLR4/MyD88. It appears that VAT TLR4 agonists, such as
S100A8/A9, act locally on ATMs via TLR4-MyD88 to initiate a
signaling cascade, resulting in the activation of NLRP3 inflam-
masome and release of IL-1b, which travels to the BM to engageFigure 7. IL-1b Signaling Contributes to Obesity-Driven Leukocytosis
(A–C) Ob/Ob mice were transplanted with WT or Nlrp3/ BM and allowed to rec
leukocytes and quantified. (B) Abundance of BM progenitor cells and (C) cell cyc
(D–F) WT and IL-1r/mice were fed an HFD for 6 months. (D) Blood leukocyte le
quantified. MCP, myeloid progenitor cells. (F) Representative cell cycle histogram
(G) IL-1R expression on CMPs and GMPs in the BM from lean or DIO mice. Expres
group. *p < 0.05.
(H and I) Competitive BMT studies. Ob/Ob mice were transplanted with equa
and allowed to repopulate for 6 weeks. Ratios of CD45.1:CD45.2 for (H) BM pr
group. *p < 0.05.
(J) BM-derived macrophages from WT, Tlr4/, or Myd88/ mice were stimulat
Dashed red line indicates control, unstimulated WT macrophages. All data are m
(K and L)WTmicewere fed anHFD for 16weeks and then given daily i.p injections
OGTT. All data are means ± SEM; n = 6 per group. *p < 0.05.
(M) Schematic overview of the proposed mechanism of how obesity promotes e
Cthe IL-1R on CMPs and GMPs, promoting their proliferation and
resulting in monocytosis and neutrophilia (Figure 7M).
DISCUSSION
Our findings suggest that chronically inflamed VAT in obesity can
signal to the BM hematopoietic progenitor cells to proliferate,
expand, and increase the production of myeloid cells. Our data
suggest that a feed-forward mechanism exists in obesity such
that inflamed adipose tissue stimulates the production of more
monocytes, leading to an exacerbation of inflammation and
associated disease processes. Our findings are consistent with
a model in which obesity-induced leukocytosis is driven by a
process where upregulation of S100A8/A9, along with other
TLR4 ligands in the VAT, signal in macrophages via the MyD88
pathway to induce the expression of Il-1b, which is then pro-
cessed by the NLRP3 inflammasome (activated by secondary
stimuli e.g., extracellular ATP, free fatty acids [FFAs], etc.) to
form mature IL-1b (Masters et al., 2011); IL-1b travels to the
BM to induce the proliferation of hematopoietic progenitor cells
via the IL-1R, ultimately resulting in monocytosis and neutro-
philia (Figure 7M).
VAT inflammation driven by the accumulation of ATMs pro-
motes IR (Osborn and Olefsky, 2012), and modulating macro-
phage recruitment alters the inflammatory milieu (Kamei et al.,
2006; Weisberg et al., 2003). However, the source of the ATMs
and the specific cellular mechanisms linking adiposity to
increased monocyte levels in obesity had not been defined.
While M2 macrophages have been reported to proliferate locally
under the control of T-helper 2 activation and release of IL-4
(Jenkins et al., 2011), this does not appear to be a major process
in obesity, as the bulk of ATMs are of the M1 variety. Previously,
Oh and colleagues showed that only a small pool of macro-
phages proliferate in the obese VAT (Oh et al., 2012). Further-
more, the majority of these CD11c+ macrophages were newly
recruited CCR2+ monocytes. While another more recent report
has also suggested that ATMs proliferate, again this is only
a small pool and can likely only sustain the ATM pool for a
short period of time (Amano et al., 2014), similar to the findings
and explanations from emerging studies on atherosclerotic le-
sions (Murphy and Tall, 2014; Randolph, 2013; Robbins et al.,
2013). Our BMT studies agree with the findings of Oh et al., sug-
gesting that there may be continuous recruitment of blood
monocytes into the VAT, where they mature into macrophages.onstitute for 5 weeks. (A) Representative flow cytometry plots depicting blood
le analysis. All data are means ± SEM; n = 5 per group. *p < 0.05.
vels. (E) Representative flow cytometry plots depicting the BM progenitors and
s and quantification. All data are means ± SEM; n = 6 per group. *p < 0.05.
sion was normalized to an isotype control. All data are means ± SEM; n = 6 per
l amounts of CD45.1 WT/ CD45.2 WT or CD45.1 WT/ CD45.2 IL-1r/ BM
ogenitor cells and (I) blood leukocytes. All data are means ± SEM; n = 5 per
ed with S100A8/A9 for 4 hr, and gene expression was assessed using qPCR.
eans ± SEM; n = 5 per group. *p < 0.05.
of Anakinra (IL-1ra; 7.5mg/kg) or saline for 10 days. (K) Blood leukocytes and (L)
nhanced myelopoiesis. See also Figure S5.
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ber of bloodmonocytes may determine the abundance of ATMs,
as we observed more WT CD45.1 monocytes and ATMs than
Il-r/ CD45.2 monocytes and ATMs. It appears reasonable to
suggest that sheer increases in the abundance of monocytes
would likely lead to increased recruitment to the VAT, and
our cBMT studies in which WT progenitors produced more
blood monocytes and more ATMs provide evidence for this.
Therefore, delineation of the mechanisms of aberrant monocyte
production in obesity is likely to be essential to understanding
ATM accumulation.
Our studies show that VAT from obese mice can directly
induce monocyte production by signaling to the hematopoietic
progenitor cells. The failure of glucose reduction to correct the
leukocytosis confirmed that a different process was driving
leukocyte production in these models of obesity/T2D compared
to the mechanism in T1D (Nagareddy et al., 2013). Glucose
reduction alone may have been insufficient because the hyper-
glycemia in thesemice was less severe and inflammatory signals
emanating from adipose tissue were more robust. We also failed
to observe an upregulation of RAGE on CMPs as we reported for
T1D, suggesting that, in obesity, these cells were limited in their
response to S100A8/A9. Instead, our studies revealed that he-
matopoietic TLR4 was playing a major role. While others have
shown that BM progenitor cells express functional TLRs that
are able to sense peripheral infections and expand immune
cell production (Nagai et al., 2006), using Myd88flox/flox mice,
we affirmed a role for TLR4-expressing ATMs. These macro-
phages sense damage-associated molecular patterns (DAMPs)
(such as S100A8/A9) and perhaps other ligands in the VAT and
produce IL-1b, which signals to the BM to manufacture more
monocytes. Monocytosis contributes to the pool of ATMs and
enhances the inflammatory milieu.
While not known to have amajor role in normal hematopoiesis,
IL-1b certainly plays an important role in inducing myeloid pro-
genitor cell proliferation in response to inflammation, to produce
neutrophils and monocytes (Hsu et al., 2011; Ueda et al., 2009),
and triggers progenitor cell proliferation via a number of mecha-
nisms in different diseases (Dinarello, 1996). Our cBMT experi-
ments clearly show that the IL-1R on hematopoietic cells is
required for the proliferation of CMPs andGMPs in obesity. How-
ever, it is important to note that this experiment cannot test the
direct source of IL-1b. That is, IL-1b could also be produced
locally in the BM to signal to these progenitor cells. However,
collectively our data (FPTs, increased plasma IL-1b levels, and
in vitro proliferation) do suggest that the signals emanate from
the VAT and are also consistent with recent studies implicating
adipose inflammasome activation as a source of IL-1b in mice
and humans (Vandanmagsar et al., 2011; Wen et al., 2011).
The endogenous TLR4 ligand (or ligands) responsible for
inducing the expression of Il-1b and key genes of the inflamma-
some in obesity has (or have) remained enigmatic. A number of
endogenous ligands have been proposed to signal via TLR4;
these include LPS, FFAs, modified low-density lipoproteins,
and DAMPs (e.g., S100A8/A9, HMGB1) (Erridge, 2010). In the
setting of obesity, other molecules such as extracellular ATP,
FFAs (Wen et al., 2011), and ceramides (Vandanmagsar et al.,
2011) have been suggested as the secondary stimuli to activate
the inflammasome in LPS-primed macrophages (Wen et al.,832 Cell Metabolism 19, 821–835, May 6, 2014 ª2014 Elsevier Inc.2011). Our data suggest that S100A8/A9, known ligands for
TRL4, may be initiating ligands that stimulate ATMs to induce
the NRLP3-inflammasome-IL-1b pathway. We also found that
weight reduction in mice and humans (Poitou et al., 2011), which
has also been reported to decrease the NLRP3 inflammasome
and plasma IL-1b levels (Vandanmagsar et al., 2011), decreased
monocytes and neutrophils, further strengthening the link be-
tween monocyte levels and IL-1b. Moreover, S100A8/A9 are
also decreased after weight loss, supporting our hypothesis
that they are initiating ligands (Catala´n et al., 2011).
Not only is monocytosis likely to be involved in promoting IR,
but it can also contribute to secondary diseases that are quite
often observed in obese individuals. Monocytosis is a well-
established risk factor of CVD (Danesh et al., 1998; Erlinger
et al., 2004; Grimm et al., 1985), and a number of studies in
mice have shown that monocytosis and enhanced monocyte
recruitment directly promote atherogenesis (Murphy et al.,
2011; Swirski et al., 2007; Tacke et al., 2007; Yvan-Charvet
et al., 2010) and inhibit lesion regression (Nagareddy et al.,
2013; Potteaux et al., 2011). Therefore, it is possible that mono-
cytosis contributes to increased CVD risk in humans with obesity
and T2D (Haffner et al., 1990). CD16+ monocytes in humans
positively correlate with the Framingham risk score and carotid
intima media thickness (Rogacev et al., 2010), well-established
indicators of CVD. Increased BMI in children is also associated
with monocytosis, with expansion of both the CD14++CD16
and CD14++CD16+ subsets (Schipper et al., 2012).
Currently, there is tremendous interest in developing therapies
that inhibit inflammatory pathways in obesity to prevent the
onset of secondary diseases such as T2D. We show here that
adipose inflammation drives monocyte production via IL-1b.
Targeting IL-1b, as well as upstream inducers of TRL4 activation
such as S100A8/A9, could potentially break a feed-forward
cycle, preventing aberrant monocyte production and recruit-
ment to the VAT or other sites of inflammation (i.e., atheroscle-
rotic lesions). Disruption of IL-1b signaling in subjects with T2D
using the IL-1Ra, Anakinra, improved insulin sensitivity and
also decreased circulating white blood cells (Larsen et al.,
2007). In this study, we found that short-term administration of
Anakinra decreased leukocyte production, resulting in fewer
ATMs and significantly improved glucose tolerance. Another
emerging idea from our studies is that leukocyte counts could
potentially be used as a biomarker for the efficacy of Anakinra
and other therapeutics that target the IL-1b pathway, especially
for diabetes and CVD. Further support for our findings comes
from the observation that Anakinra also decreases leukocyte
levels in other inflammatory diseases (Aksentijevich et al.,
2009; Goldbach-Mansky et al., 2006; Pascual et al., 2005).
Overall, our study demonstrates that VAT can signal to the BM
to induce monocyte production and illustrates a number of
targetable pathways to prevent aberrant monocyte production,
systemic inflammation, and, possibly, risk of secondary dis-
eases (e.g., CVD and T2D) in obesity. While our study suggests
amajor role ATM-derived IL-1b signaling to increase BMmyeloid
progenitors, it is likely that additional cytokines andmechanisms
are also involved in obesity. For example, Tsuchiya and col-
leagues have shown that FoxO ablation in macrophages leads
tomyeloid progenitor expansion in the setting of hypercholester-
olemia (Tsuchiya et al., 2013), suggesting that excessive insulin
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Obesity Drives Myelopoiesissignaling associated with hyperinsulinemia could also be a
factor contributing to excessive leukocyte production in insu-
lin-resistant states. Our study also indicates that therapeutic in-
terventions that block leukocytosis could alleviate secondary
complications of obesity. Inhibitors that are more specific for
obesity-driven IL-1b could be developed to target the NLRP3 in-
flammasome (i.e., CRID3; Coll and O’Neill, 2011) or the upstream
ligands of TLR4, such as S100A8/A9. Finally, our study reveals
that monocyte and neutrophil levels could be used as an indica-
tor of adipose tissue health in metabolic diseases.
EXPERIMENTAL PROCEDURES
Mice and Treatments
Eight- to 12-week-old male mice were used for this study: WT, B6.V-Lepob/J
(Ob/Ob), B6.B10ScN-Tlr4lps-del/JthJ (Tlr4/), Rage/, and Myd88/ in
C57BL/6J backgrounds. WT, Ob/Ob, Tlr4/, Myd88/, and DIO mice were
purchased from the Jackson Laboratory. Rage/ mice were provided by
Yasuhiko Yamamoto (Kanazawa University). BM for studies involving IL-
1r/ and Nlrp3/ mice was obtained from a colony maintained at the
Pennington Biomedical Research Center or from Walter and Eliza Hall. BM
for Myd88flox/flox, Myd88flox/flox LysMCre, and Myd88flox/flox CD11c Cre was
provided by Dr. RuslanMedzhitov (Yale University). The SGLT2i (Dapagliflozin)
was fromBristol-Myers Squibb and administered in drinking water at 25mg/kg
(body weight)/day for 4 weeks. Recombinant murine leptin was administered
via injection (i.p.) at a dose of 1 mg/kg/day for 7 days. All mouse protocols
were approved by the Institutional Animal Care and Use Committees of
Columbia University, Pennington Biomedical Research Institute, and the
Animal Ethics Committees of the Alfred Medical Research and Education
Precinct, and the Walter and Eliza Hall Institute of Medical Research.
BMT Studies
Recipient mice were given 100 mg/l neomycin 2 weeks before and after BMT.
WT mice were lethally irradiated (with 2 3 6.5 Gy from a cesium gamma
source) and transplanted with BM (5 3 106 cells) from the donor mice and
allowed to reconstitute over a 5 week period.
FPT Studies
VAT was harvested from the donor mice, washed in PBS, and cut into 100 mg
pieces. WT lean recipient mice were anesthetized with ketamine (100 mg/kg)/
xylazine (10 mg/kg). A small incision was made to access the subcutaneous
space, and the VAT pads were carefully inserted. The wound was sutured
closed, and monocyte levels were measured over time. Each recipient mouse
received a transplant from an individual donor.
Flow Cytometry
Blood Leukocytes
Monocytes (total and subsets) and neutrophils were identified from whole
blood as described elsewhere (Murphy et al., 2011). Monocytes were identified
as CD45hiCD115hi and further identified as Ly6-Chi and Ly6-Clo; neutrophils
were identified as CD45hiCD115loLy6-C/Ghi.
Hematopoietic Stem Cells
Hematopoietic stem and progenitor cells from the BM and spleen were
analyzed by flow cytometry as described elsewhere (Murphy et al., 2011).
HSPCs were identified as lineage, Sac1+, and ckit+, while the hematopoietic
progenitor subsets were separated by using antibodies to CD16/CD32
(FcgRII/III) and CD34. CMPs were identified as lin, Sca1, ckit+, CD34int,
and FcgRII/IIIint; GMPs were identified as lin, Sca1, ckit+, CD34int, and
FcgRII/IIIhi. Cell cycle analysis was performed using DAPI (Sigma). Flow
cytometry was performed using an LSRII (for analysis [BD Biosciences]) or
FACS Aria (for sorting [BD Biosciences]), both machines running FACS DiVa
software. All flow cytometry data were analyzed using FlowJo software (Tree
Star Inc.)
In Vitro Proliferation Assay
BMprogenitor cells were cultured for 16 hr in the presence of cytokines essen-
tial for hematopoietic growth: stem cell factor (100 ng/ml, R&D Systems), IL-3C(6 ng/ml, R&D Systems), and granulocyte macrophage/colony-stimulating
factor (2 ng/ml, R&D Systems), with the test samples indicated for the respec-
tive experiments. For proliferation measurements, cells were incubated with
10 mMof 5-ethynyl-20-deoxyuridine (EdU) for 12 hr. Proliferationwasmeasured
by determining the amount of EdU incorporation or percentage of cells in the
G2/M phase by staining with DAPI and quantified by flow cytometry.
Statistics
A two-tailed Student’s t test or one-way ANOVA with a Bonferroni mul-
tiple-comparison posttest was used to analyze data (GraphPad Prism). A
p value > 0.05 conferred significance. Data are mean ± SEM unless otherwise
indicated (i.e., error bars depict SEM).
Detailed methods are available in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2014.03.029.
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